Method for manufacturing highly purified lactoferrin and lactoperoxidase from milk, colostrum and acid or sweet whey

The use of a monolith column with pH and salt gradients in chromatography effectively isolates lactoferrin and lactoperoxidase from milk or whey, overcoming efficiency limitations of existing methods, achieving high purity and iron-binding capacity suitable for large-scale production.

JP2024166338APending Publication Date: 2024-11-28ARHEL PROJEKTIRANJE IN INZENIRING D O O
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024160485
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-11-06
Filing Date
2024-09-17
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current chromatography methods for isolating lactoferrin and lactoperoxidase from milk or whey face challenges such as broadened peaks due to diffusive mass transfer, increased elution volume, and pressure drops, leading to lower purity and efficiency.

Method used

A method using a monolith column with strong cation exchanger properties and a combination of pH and salt gradients for chromatographic separation, allowing for the isolation of highly pure lactoferrin and lactoperoxidase with a pH gradient ranging from 4.0 to 12.0 and a conductivity gradient from 5 mS/cm to 55 mS/cm, achieving purities greater than 98% and 78%, respectively.

Benefits of technology

The method achieves high purity and high iron-binding capacity of lactoferrin and lactoperoxidase, with C values over 70% and A values less than 3.9%, while maintaining high biological activity and efficiency, suitable for large-scale production without chemical alteration of the medium.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024166338000001_ABST
    Figure 2024166338000001_ABST
Patent Text Reader

Abstract

To provide a high-purity and high-activity lactoferrin composition.SOLUTION: The present invention provides a method for manufacturing a fraction comprising the proteins lactoferrin and / or lactoperoxidase from a source containing at least one of these proteins, wherein the source is selected from the group consisting of milk, colostrum, acid or sweet whey, by means of a chromatographic separation process with a monolithic column having strong cation exchanger properties, wherein in the separation process, a pH gradient or a combined pH and salt gradient elution is employed after loading the source to the column. Further disclosed is a composition comprising lactoferrin or lactoperoxidase having a C value of more than 60% and A value of more than 1%.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a method for producing a fraction containing lactoferrin protein or lactoperoxidase protein from a raw material containing at least one of lactoferrin protein or lactoperoxidase protein, and to a highly purified lactoferrin protein or lactoperoxidase protein. [Background technology]

[0002] Lactoferrin (LF) and lactoperoxidase (LPO) are functional trace proteins present in milk, whey and colostrum. LF is an 80 kDa glycosylated protein that is capable of responding to various physiological and environmental changes and is therefore considered an important component in the host's first line of defense. The structural characteristics of LF include the Fe 3+ In addition to its homeostatic functions, LPO exerts broad-spectrum antibacterial activity against a wide range of bacteria, fungi, yeasts, viruses and parasites; anti-inflammatory and anticarcinogenic activities; and several enzymatic functions, which are common to all transferrins.[1] LPO plays a vital role in the protection of the mammary gland and neonatal intestine against pathogenic microorganisms and is involved in the degradation of various carcinogens and in the protection of animal cells against the effects of peroxidation.[2]

[0003] LF can bind iron. Natural LF contains 15-20% holo LF, which contains iron. The remainder is apo LF, which does not contain iron

[32] . In theory, apo LF has a rather low iron saturation (already bound iron - A value). The theoretical A value of apo LF is about less than 3%. Furthermore, apo LF has a high iron-binding potential (iron capacity - C value). The C value of apo LF is about more than 50%. Highly purified and undenatured apo LF has the potential to have a higher C value of more than 70%. On the other hand, holo LF has a high A value (more than 50%) and a low C value (less than 10%). The higher the C value of isolated LF, the higher the iron-binding potential of LF. High iron-binding potential results in a higher level of antibacterial activity, since active LF removes iron required for microbial growth.

[0004] Recently, LF and LPO have been isolated from milk and dairy processing by-products (e.g., whey) by many different methods, such as (I) isolation by paramagnetic particles bearing poly(glycidyl methacrylate) with heparin ligands [3], (II) use of cationic surfactants (e.g., cetyldimethylammonium bromide) [4], (III) various chromatographic methods (e.g., cation exchange or affinity chromatography) [1, 2, 5-10], and (IV) other methods (e.g., hydrophobic ionic liquids

[11] ). In general, chromatographic methods, especially ion exchange chromatography, represent a relatively low-cost and fast method for separating LF

[12] . Chromatographic methods are also superior to other methods due to their robustness and repeatability. The most common method for chromatographic purification of LF and LPO uses strong cation exchange resin particles and membrane or monolith columns [13-15].

[0005] Current chromatography has several drawbacks, including: (I) as the flow rate increases, peaks broaden due to diffusional mass transfer within the pores, so that increasing the flow rate requires a less steep gradient to obtain the same resolution; (II) increased flow rate reduces the time of the chromatography step but at the same time increases the elution volume; and (III) the column length increases the pressure drop across the column, which becomes a limiting factor for the flow rate.

[0006] In the chromatographic purification process, LF and LPO present in milk or whey are bound to the surface of a strong cation exchanger under defined conditions and then collected in elution fractions using buffers with high pH or high salt concentration. To simplify the separation process, LF and LPO are often eluted using several buffers with either high ionic strength or pH > 9 in a step mode. Such methods often result in a relatively high purity (60-95%) of the desired protein fraction in one chromatographic step. For desalting, concentration and purity improvement, ultrafiltration is often introduced to remove traces of low molecular weight impurities. The obtained protein concentrate is then often dried by freeze-drying or spray-drying. Wang et al. showed that freeze-dried LF contains less water (about 2-3%) compared to spray-dried LF (≈5%), whereas spray-dried LF exhibits a slightly lower degree of denaturation and 6-7% higher antioxidant activity, closer to fresh liquid LF

[18] . Spray drying [1] has been used successfully to produce amorphous LF powder with intact molecular structure and high antioxidant capacity.

[0007] European Patent No. 0418704

[19] describes a process for the separation, purification and recovery of milk proteins capable of binding iron using an ion-exchange chromatography column containing resin particles with surface sulfonic acid groups. LF is isolated by pH / conductivity step elution mode, and the purity of the final product is claimed to be greater than 90%. Ultrafiltration is also required to remove traces of low molecular weight impurities, and the final purity of LPO and LF is claimed to be greater than 90%.

[0008] The process described in EP 1 466 923

[20] involves a chromatography step using strongly acidic cation exchange resin (particles), resulting in isolated LF with a purity in the range of 79–91%.

[0009] WO 2006 / 119644

[21] describes a method to purify LF, stabilize it in solution and improve its activity. The process is intended to further purify already isolated low-purity LF. Purification is carried out using hydrophobic adsorbents (particles) in the presence of an acidic aqueous solution containing a certain concentration of charged excluded solutes. The final purity of the obtained LF was greater than 95%.

[0010] US Patent No. 5,861,491

[13] describes a method for isolating human LF and other related LF species from milk, typically bovine milk, including human LF produced by expression of a transgene encoding recombinant human LF (rhLF). In general, milk or milk fractions containing hLF are contacted with a strong cation exchange resin at relatively high ionic strength to suppress binding of non-LF proteins and other substances to the strong cation exchange resin. The resin particles are then separated from the milk by centrifugation, and the LF bound to a given cation exchange resin is then eluted with several buffers with various salt concentrations in a step mode. The purity of the top fractions of hLF and bLF is greater than about 95%.

[0011] European Patent No. 0348508

[22] discloses the isolation of LF from raw milk using sulfonated cross-linked polysaccharide resins (particles).

[0012] The LF adsorbed on the column is eluted in step mode with a buffer having a higher NaCl concentration. The purity of LF obtained from defatted human colostrum was determined to be 98%, and that of bovine LF was determined to be 95%.

[0013] The method described in U.S. Pat. No. 6,096,870

[23] uses whey proteins (immunogins) This paper relates to the separation of whey proteins (immunoglobulins, β-lactoglobulin, α-lactalbumin, bovine serum albumin, LF), in particular to the sequential separation of whey proteins into distinct fractions using prepacked chromatography columns with strong cation exchange resin particles. The sequential elution of the protein fractions is achieved using buffers of suitable pH and ionic strength in a stepwise mode. The purity of the final spray-dried product was greater than 80% for immunoglobulins, greater than 75% for BSA and LF, and greater than 85% for β-lactoglobulin.

[0014] US Patent No. 8,603,560

[24] describes a process for isolating milk proteins from milk or whey using a cation exchange resin packed in a column. Elution is facilitated by a step change in pH or ionic strength. The final LF purity was 80%.

[0015] Canadian Patent No. 2128111

[25] describes a process for the isolation of LF and LPO from milk and dairy products on an industrial scale. Isolation is achieved by adsorption of the proteins onto a cation exchanger and elution of the proteins separately or simultaneously by stepwise elution with one or more salt solutions. No information is given on the final purity of the isolated proteins.

[0016] European Patent No. 0253395

[26] discloses a process for isolating bovine LF from milk in high purity using a weakly acidic cation exchange resin. The LF is recovered from the ion exchanger by stepwise elution with sodium chloride solutions having different concentrations. According to the conventional Rohrer method, the purity of the resulting LF is determined to be 90-99%.

[0017] US Patent No. 5,596,082

[27] discloses a process for the isolation of LF and the enzyme LPO from milk and milk products on an industrial scale. The process involves adsorption of these proteins onto a cation exchanger by passing milk or a milk derivative through the cation exchanger. The elution of the proteins is facilitated by stepwise elution with different salt concentrations. The final purity of LPO and LF was 93% and 94%, respectively.

[0018] The invention disclosed in US Patent No. 9,115,211

[28] describes the isolation of LF using a cation exchange resin. The LF obtained by the described method is more than 95% pure, substantially free of LPS, endotoxin and angiogenin, and has an iron saturation of 9% to 15%.

[0019] European Patent Application Publication No. 2421894

[29] describes a method for preparing low-iron LF with an iron saturation level of less than 10% or more preferably about 9% to 3.89%. The low-iron LF produced by this process exhibits enhanced antibacterial activity compared to standard LF. The process uses an acid and a solvent. Fe 3+ After release, the added process aids were removed by UF and DF processes. The resulting product is light yellow / light brown in color with iron saturation (by HPLC / X-ray fluorescence (XRF)) of 3.89%-5.1%.

[0020] WO 2014 / 207678

[30] discloses a method for purifying LF from secretions, which comprises alkalizing the secretions, contacting the alkalized secretions with air, and precipitating LF from the alkalized secretions with an organic solvent (acetone).

[0021] WO 1995 / 022258

[31] discloses methods for purifying human LF from milk, particularly from the milk of non-human species, and for separating human LF from unwanted macromolecular species present in milk, including from non-human LF species. To achieve the isolation, a strong cation exchange resin (e.g., S Sepharose™) is used. Proteins (such as LF) are eluted using a stepwise salt and pH gradient.

[0022] G. Majka et al. (A high-throughput method for quantification of iron saturation in lactoferrin preparations, Anal. Bioanal. Chem., 405, 5191-5200, 2013) disclose a method for obtaining bovine lactoferrin with low iron content. To obtain lactoferrin with low iron content, it was not sufficient to perform ion exchange chromatography alone. Therefore, ion exchange chromatography was combined with an extensive dialysis method against 100 mM citrate buffer for 24 hours. Summary of the Invention [Problem to be solved by the invention]

[0023] One object of the present invention is to provide a composition of highly pure, highly active lactoferrin.

[0024] Another object of the present invention is to provide a method suitable for solving at least some of the problems of the prior art.

[0025] Highly active lactoferrin is characterized by a rather low iron saturation (already bound iron - A value) and a high iron binding potential (iron binding capacity - C value).

[0026] Another object of the present invention is to provide a composition containing lactoperoxidase in high purity.

[0027] It is yet another object of the present invention to provide a method for producing lactoferrin or lactoperoxidase in high purity from raw materials containing these proteins. [Means for solving the problem]

[0028] These objects are achieved by a method for producing a fraction containing lactoferrin protein or lactoperoxidase protein from a raw material containing at least one of these proteins, said raw material being selected from the group consisting of milk, colostrum, acid or sweet whey, utilizing a chromatographic separation process using a monolithic column with strong cation exchanger properties, in which a pH gradient or a combination of pH and salt gradient elution is used after introduction of the raw material into the column.

[0029] In one embodiment of the present invention, the pH gradient is typically initiated within a pH range of 4.0 to less than 8.0, preferably within a pH range of 4.0 to 7.5, more preferably within a pH range of about 4.0 to less than about 7, and particularly within a pH range of about 4.5 to less than about 6.5.

[0030] In other embodiments of the invention, the pH gradient typically terminates in a pH range of about 8-13 or less, preferably in a pH range of 8-12, especially in a pH range of 8-12 or less.

[0031] It may be advantageous to filter the feed before introducing it into the column.

[0032] In yet another embodiment of the invention, the salt gradient is performed by increasing the salt concentration, in particular the salt gradient corresponds to a conductivity in the range of about 5 mS / cm to about 55 mS / cm. To avoid interference with the pH of the buffer, it is advisable to use a neutral salt to adjust the salt concentration. Salts used in food industry processes, typically sodium chloride, are particularly advantageous.

[0033] The pH gradient used in combination with the above-mentioned salt gradient typically starts at a pH value in the pH range of 4.0 to less than 8.0, preferably in the pH range of 4.0 to 7.5, more preferably in the pH range of 4.0 to less than 7, in particular in the pH range of 4.5 to less than 6.5. The pH gradient used in combination typically terminates in the pH range of 8 to less than 13, preferably in the pH range of 8 to 12, in particular in the pH range of 8 to less than 12.

[0034] In yet another embodiment of the present invention, fraction A can be recovered which elutes in the pH range of about 8 to less than about 11, preferably in the pH range of 8.0 to 10.0, more preferably in the pH range of 8.2 to 10.0, particularly in the pH range of about 8.9 to about 10. This fraction typically contains lactoperoxidase.

[0035] In yet another embodiment of the present invention, a fraction B eluted in a pH range of more than 10 to 12.0, preferably more than 10.4 to 12, preferably more than about 11 to about 12, particularly more than about 11 to about 11.7, can be collected. This fraction typically contains lactoferrin.

[0036] In a particularly useful embodiment of the method of the invention, the chromatographic separation process comprises: (i) adjusting the pH of the feedstock to a value below 7, in particular below pH 6.5; (ii) contacting the feed of step (i) with a monolith column having strong cation exchange properties; and then (iii) passing a gradient buffer through the column, thereby increasing the pH value; and (iv) recovering fraction A which elutes in the pH range of about 8 to less than about 11, preferably in the pH range of 8.0 to 10.0, preferably in the pH range of 8.2 to 10.0, in particular in the pH range of about 8.9 to about 10; and / or (v) recovering fraction B which is eluted in a pH range of more than 10 to 12.0, preferably in a pH range of more than about 10.4 to about 12, preferably in a pH range of more than 11.0 to 12.0, particularly in a pH range of more than about 11 to about 11.7; (vi) optionally further processing fraction A and / or fraction B, in particular by treatments such as neutralization, concentration and storage; Includes.

[0037] It may be advantageous to filter the lactoferrin and / or lactoperoxidase containing raw material prior to step (ii).

[0038] In another embodiment of the method of the present invention, the monolith column may be equilibrated with an equilibration buffer having a pH value of less than about 7, in particular less than about 6, prior to step (ii).

[0039] The monolithic columns having strong cation exchanger properties are in particular selected from the group consisting of SO3H-modified monolithic columns, -COOH-modified monolithic columns, -OSO3H-modified monolithic columns or -OPO3H-modified monolithic columns. In the context of the present invention, SO3H, -COOH, -OSO3H or -OPO3H-modified monolithic columns also include the salts corresponding to the acidic moieties, in particular their alkali salts such as sodium and potassium salts, for example SO3Na, -COONa, -OSO3Na or -OPO3Na or SO3K, -COOK, -OSO3K or -OPO3K.

[0040] According to the method of the present invention, fraction B typically contains lactoferrin and fraction A, which elutes at a lower pH value than fraction B, typically contains lactoperoxidase.

[0041] In a further embodiment of the invention, prior to step (iii) or step (iv), the column may be flushed with an equilibration buffer.

[0042] Typically, the fraction containing lactoferrin and lactoperoxidase may be subjected to further processing, such as for example drying, in particular drying by spray drying.

[0043] The method of the present invention provides lactoferrin or lactoperoxidase with high purity. The purity of lactoferrin is more than 98%, and the purity of lactoperoxidase is more than 78%. Furthermore, the C value of lactoferrin is more than 50% or more than 60%, and the A value of lactoferrin is more than 1%. Preferably, the C value of lactoferrin is more than 70%, and the A value of lactoferrin is more than 2%. Preferably, the C value of lactoferrin is more than 70.0%, preferably between 70.0% and 80.0%, more preferably between 70.0% and 77.0%. Preferably, the A value of lactoferrin is more than 2.0%, preferably less than 3.9%, preferably between 1.0% and 7.0%, preferably between 2.0% and 7.0%, preferably between 2.0% and 5.0%, more preferably between 2% and 4%.

[0044] According to another embodiment of the invention, typically after step (iv) or step (v), the monolith column may be washed by flushing with a buffer having a pH above about 12.

[0045] The subject of the present invention is also a composition comprising lactoferrin or lactoperoxidase obtained by the method of the present invention.The C value of lactoferrin is greater than 60% and the A value is greater than 1%.Preferably, the C value of lactoferrin is greater than 70% and the A value is greater than 2%.Preferably, the C value of lactoferrin is greater than 70.0%, preferably between 70.0% and 80.0%, more preferably between 70.0% and 77.0%.

[0046] Preferably, the A value of lactoferrin is between 1.0% and 7.0%, preferably between 2.0% and 7.0%, preferably between 2.0% and 5.0%, more preferably between 2% and 4%, preferably greater than or equal to 2.0% and / or preferably less than 3.9%.

[0047] Preferably, the A+C value of the product of the invention is at least 61%, at least 72%, or at least 73%.

[0048] The method of the present invention comprises the steps of: A rapid and simple method for the isolation of LF and LPO from milk, colostrum and acid or sweet whey, A single chromatographic step isolation process using a linear pH gradient for LF and LPO isolation, which allows obtaining highly pure target proteins (e.g., LF with purity >98%); The product (LF protein) obtained by the disclosed method has a high activity (C value > 70%, C value determination kit for LF, NRL Pharma Co., Ltd.) according to the established method for measuring the unsaturated iron binding capacity (UIBC) and a low amount of already bound iron (A value < 3.9%, A value determination kit for LF, NRL Pharma Co., Ltd.), which are excellent characteristics among LF available on the market. The said product is produced by an economical and resource-friendly method that is performed on-site (on a monolithic cation exchanger) without the use of special chemicals. A method that allows the production of LF that contains low amounts of iron (A value less than 3.9%) and is at the same time free of angiogenin, A method that allows the production of LF with high total biological activity (C value + A value > 72%), A method that allows for cost-effective production of LF and LPO with high purity and bioactivity that can be easily scaled up to manufacturing scale; The entire process of LF / LPO isolation, including chromatography, concentration / desalting and drying processes, which allows for an overall recovery of more than 85% of LF; -High flow rate of mobile phase (700L / m) without impeding high resolution of proteins 2 / h) Chromatographic processes that enable and result in highly productive processes; processes that do not introduce chemicals into the medium containing the proteins to be isolated (e.g. whey) or in any other way change its properties, thereby making the medium more usable in other biochemical and industrial processes; A method allowing the production of LF with a defined proportion of already bound iron, to provide. [Brief description of the drawings]

[0049] [Figure 1] Figure 1 shows a chromatogram of an LF elution peak that is composed of LF elution subpeaks. This phenomenon is due to a slight difference in the LF isoelectric point (IEP) with iron content. Voswinkel et al.

[32] showed that a reduction in iron content results in a slight decrease in the IEP of LF. [Figure 2A] FIG. 2A shows a chromatograph of acid whey. [Figure 2B] FIG. 2B shows the chromatographs of the commercial LF product and LF. [Diagram 3] FIG. 3 shows the LF isolation scheme from acid whey using one 8 L monolith column (CIMmultus™ SO3, BIA Separations) and basic information about the mass balance of the process. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0050] A monolithic column with strong cation exchange groups, CIMmultus™ SO3-Strong CEX (BIA Separations), was tested in various elution modes for the separate isolation of LF and LPO from filtered whey or milk. The LF / LPO loading was performed at the native pH of the whey, and the two target proteins were separately eluted by (I) a stepwise increase in pH, (II) a conductivity step, (III) a linear conductivity gradient, and (IV) a linear pH gradient.

[0051] In the comparative step elution mode, the purity of the LF obtained was about 95%, and in the conductivity gradient the purity was slightly higher than 95%. Surprisingly, it was found according to the invention that elution with an increasing pH gradient, especially a linearly increasing pH gradient, achieves a protein purity of more than 98%. The purity was verified by HPLC, SDS-PAGE analysis, bioanalyzer and SEC chromatography. The method of the invention provides these results at a manufacturing scale with a single chromatographic step. It should be noted that the calculated purity of the product obtained by the method of the invention is more than 118% according to the Rohrer method

[26] used for purity calculation in EP 0253395. This established calculation method is outdated and appears no longer suitable for accurate determination of LF purity.

[0052] In the case of linear pH gradient elution, the LF elution was found to consist of several small subpeaks (Figure 1). The latter suggests that the LF was separated from low to high protein iron content levels. The reasons for this have already been discussed and proven by others

[32] .

[0053] The concentrated LF aqueous dispersion was dried by spray drying or freeze drying, and then the unsaturated iron-binding capacity (UIBC) of the LF was measured. According to the iron colorimetric assay kit provided by NRL Pharma Co., Ltd. (the detailed principle was published by Ito et al.

[33] ), the LF obtained by the method of the present invention had an iron saturation degree (already bound iron - A value) between 2% and 4.9%. The iron-binding potential (iron-binding capacity - C value), also called unsaturated iron-binding capacity (UIBC), was above 70%. The above results are higher than those of commercial products, whose A and C values ​​are located between 4.6-11.7% and 34.4-52.1%, respectively (see Table 1). At the same time, the total biological activity (C value + A value) of the commercial products is usually lower than that of the product of the present invention. Very low.

[0054] [Table 1]

[0055] The method of the present invention provides a method for producing a fraction containing lactoferrin protein or lactoperoxidase protein from a raw material containing at least one of these proteins, the raw material being selected from the group consisting of milk, colostrum, acid or sweet whey, utilizing a chromatographic separation process using a monolith column with strong cation exchanger properties, in particular a -SO3H modified monolith column, in which pH gradient elution is utilized after the raw material is introduced into the column.

[0056] Monolith columns are generally chromatographic separation devices with a hollow body that contains a porous solid material that is a polymerisate of a monomer, the pores of which are formed, for example, during a polymerization process (U.S. Pat. Nos. 4,923,610, 4,952,344, 4,889,623).

[0057] Suitable devices are described in the prior art, for example in EP 1058844 and EP 777725, and are available on the market. The monolithic chromatographic materials used in the present invention are modified with -SO3H moieties, which are in particular exposed on the surface of the porous material. The surface modification with -SO3H groups provides the material with so-called strong cation exchange properties (CAX). The skilled person knows, for example, other materials classified as weak cation exchangers. In contrast, anion exchangers (AEX) can be used for other purposes.

[0058] The pH gradient chromatography is carried out by increasing the pH from a starting value to an end point. It can be designed to be approximately linear, but it can also have a different trajectory as long as the result of the present invention, i.e., the lactoferrin and / or lactoperoxidase of the present invention, is obtained. Those skilled in the art know how to carry out such gradient chromatography. The optimization of the cation gradient chromatography conditions based on the explicit and implicit disclosure of the present invention is within the skill of those in the art. The experiment is within the scope of normal human activity and does not require undue burdensome experimentation.

[0059] To establish reproducible processing conditions, it may be advantageous to equilibrate the monolith column before the actual separation by pH gradient. In this case, the column is flushed with equilibration buffer. Typically, the column is flushed with a volume of equilibration buffer corresponding to 8-12 times the dead volume of the column. The choice of the starting pH value of the chromatography is influenced to some extent by the pH value of the feedstock containing LF and / or LPO. For example, if acid whey is the feedstock for LF and / or LPO, the pH value for equilibration may be 4.6, while the pH value when using sweet whey may be higher, i.e. 5.0-6.5.

[0060] It may be advantageous to filter the feed before introducing it into the column. Generally, filtration means used in the dairy industry can be used. Particularly useful are ceramic TFF filters, spiral wound membranes or other continuous filtration methods.

[0061] In principle, pH gradient chromatography can be started after the introduction of the feedstock into the monolith column. However, before starting pH gradient chromatography, it may be useful to additionally flush the column at a pH value close to the equilibrium conditions to remove impurities. This aids in the separation of the proteins produced, since the separation of LF and / or LPO is not contaminated by proteins or other contaminants that elute at that pH value.

[0062] The pH gradient typically begins at a pH value in the pH range of 4.0 to less than 8.0, preferably in the pH range of 4.0 to 7.5, preferably in the pH range of about 4.0 to less than about 7, especially in the pH range of about 4.5 to less than about 6.5. The pH gradient typically ends in the pH range of about 8 to less than 13, preferably in the pH range of 8 to 12, especially in the pH range of 8 to less than 12. Figure 1 illustrates a typical trajectory of pH gradient chromatography.

[0063] It should be noted that the ionic strength of the elution buffer may also have some effect on the separation. The ionic strength may also follow an increasing gradient during the chromatographic separation to cover the required pH gradient. The pH gradient required to be used in combination with the aforementioned salt gradient typically starts at a pH value in the pH range of 4.0 to less than 8.0, preferably in the pH range of 4.0 to 7.5, preferably in the pH range of 4.0 to less than 7, in particular in the pH range of 4.5 to less than 6.5. The pH gradient used in combination with the salt gradient typically ends in the pH range of 8 to less than 13, preferably in the pH range of 8 to 12, in particular in the pH range of 8 to less than 12.

[0064] For example, LPO elutes in a pH range of about 8 to less than about 11 when the ionic strength corresponds to a conductivity of about 15 mS / cm, but elutes at a lower pH in the pH range of about 6.6 to about 7.5 when the conductivity increases from 4 mS / cm to 55 mS / cm, preferably from 5 mS / cm to 55 mS / cm. The elution of LF follows a similar morphology. LF elutes in a pH range of about 10.7 to about 11.7 when the conductivity remains medium and constant, but LF elutes at a lower pH in the pH range of about 9.6 to about 10.7 when the conductivity increases from 4 mS / cm to 55 mS / cm, preferably from 5 mS / cm to 55 mS / cm. The ionic strength, i.e. the conductivity, can be adjusted by adding an appropriate salt. The pH value of the elution buffer may be adjusted by using an appropriate salt.

[0065] Fraction A, which elutes in the pH range of about 8 to less than about 11, preferably in the pH range of 8.0 to 10.0, preferably in the pH range of 8.2 to 10.0, in particular in the pH range of about 8.9 to about 10, or in the pH range of about 6.6 to about 7.5 at higher conductivity of about 5 to 55 mS / cm, is collected. This fraction typically contains lactoperoxidase. Fraction B eluting in the pH range, particularly in the pH range of greater than about 11 to about 11.7, or in the pH range of about 9.6 to about 10.7 (higher conductivity: about 5 to 55 mS / cm), is collected. This fraction typically contains lactoferrin.

[0066] The following describes typical steps of the method of the present invention. The pH range in which LF and LPO elute corresponds to a moderate conductivity of about 15 mS / cm. The chromatographic separation process is (i) adjusting the pH of the feedstock to a value below 7, in particular below pH 6.5; (ii) contacting the feedstock of step (i) with a monolith column having strong cationic properties, in particular a -SO3 modified monolith column, and then (iii) passing a gradient buffer through the column, thereby increasing the pH value; and (iv) recovering fraction A which elutes in the pH range of about 8 to less than about 11, preferably in the pH range of 8.0 to 10.0, preferably in the pH range of 8.2 to 10.0, in particular in the pH range of about 8.9 to about 10; and / or (v) recovering fraction B which is eluted in a pH range of greater than 10 to 12.0, preferably greater than about 10.4 to about 12, preferably greater than 11 to 12, particularly greater than about 11 to about 11.7; (vi) optionally further processing fraction A and / or fraction B, in particular by treatments such as neutralization, concentration and storage; Includes.

[0067] To remove unwanted materials, the lactoferrin and / or lactoperoxidase containing raw material is filtered through a ceramic filter prior to step (ii).

[0068] The monolith column is equilibrated prior to step (ii) with an equilibration buffer having a pH value of less than about 7, in particular less than about 6. Prior to step (iii) or step (iv), the column is flushed with an equilibration buffer.

[0069] After the fractions containing lactoferrin and lactoperoxidase are collected, they are further processed by spray drying.

[0070] The lactoferrin or lactoperoxidase obtained is of high purity. The purity of lactoferrin is more than 98% and the purity of lactoperoxidase is more than 78%. Furthermore, the C value of lactoferrin is more than 60% and the A value of lactoferrin is more than 1%. Preferably, the C value of lactoferrin is more than 70% and the A value of lactoferrin is more than 2%. Preferably, the C value of lactoferrin is more than 70.0%, preferably between 70.0% and 80.0%, more preferably between 70.0% and 77.0%. Preferably, the A value of lactoferrin is between 1.0% and 7.0%, preferably between 2.0% and 7.0%, preferably between 2.0% and 5.0%, more preferably between 2% and 4%, preferably more than 2.0% and / or preferably less than 3.9%.

[0071] According to another embodiment of the invention, typically after step (iv) or step (v), the monolith column is washed by flushing with a buffer having a pH above about 13.

[0072] The washing step is performed by rinsing the column with deionized water (10-15 cv), 1 M NaOH (4-10 cv), and again with water (>30 cv) for a contact time of 1-3 h. This step may be performed after every 8-10 chromatographic runs.

[0073] The uniqueness of the novel approach according to the method of the present invention is that (I) the source from which the protein is isolated ( (II) it uses small amounts of inexpensive chemicals (buffers) unlike other processes (e.g., EP 2 421 894

[29] ); (III) it provides separate fractions of LPO and LF with high purity; (IV) it allows the production of LF with a defined percentage of iron already bound; and (V) it results in a high protein recovery of more than 85%, including the process steps of desalting / concentration and drying of the protein eluate dispersion.

[0074] All references cited herein are hereby incorporated by reference in their entirety, unless they contradict an explicit teaching of this specification.

[0075] The present invention is further described and illustrated by the following non-limiting examples. EXAMPLES

[0076] <Analysis> [HPLC analysis] To identify LF and LPO in the samples, a chromatography system (PATfix™, BIA Separations, Ajdovščina, Slovenia) equipped with a MWD multi-wavelength detector and a conductivity monitor with a pH measurement kit was used. Chromatographic separation was performed on a CIMac SO3-0.1 (pore 1.3 μm, BIA Separations, Ajdovščina, Slovenia) analytical column using two sodium phosphate monobasic buffers (25 mM, pH=7.5) in a conductivity gradient mode increasing from 3.5 mS / cm to 152 mS / cm. Elution of the analyzed proteins was monitored by the MWD detector at 226 nm. Detailed information about the chromatographic method is shown in Table 2 and chromatograms of some analyzed samples are shown in Figures 1 and 2. All samples were filtered using CHROMAFIL™ A-45 / 25 (pore size 0.45 μm) mixed cellulose ester filters before analysis.

[0077] [Table 2]

[0078] [Determination of C and A values] To determine the C and A values ​​of the dried LF samples, an iron colorimetric assay kit provided by NRL Pharma Co., Ltd. (Japan) was used (the detailed principle is described by Ito et al.

[33] ). published), we used the same approach described in the literature [33, 34] in combination with an HPLC method to determine the A values ​​of dry and liquid samples.

[0079] [Determination of C value] To determine the C value of LF, LF was saturated with a known excess of iron. Residual iron was stained with a chelating agent (maximum absorbance 760 nm). Residual iron was quantified spectrophotometrically at 760 nm. Serial dilutions of the iron complex were prepared and a calibration curve was determined spectrophotometrically at 760 nm. Bound iron was calculated by subtracting residual iron from added iron. C values ​​are shown relative and the calculated theoretical iron binding capacity of LF (each molecule of LF can bind two iron atoms) is set as 100%.

[0080] [Calculation of C value]

number

[0081] [Determination of A value] To determine the A value of LF, LF is modified with a modification agent and the released iron is stained with a chelating agent (maximum absorption wavelength 760 nm). The released iron is quantified spectrophotometrically at 760 nm. Serial dilutions of the iron complex are prepared and a calibration curve is determined spectrophotometrically at 760 nm. The already bound iron (A value) is shown relatively, with two iron atoms bound to one LF molecule defined as 100%.

[0082] [Calculation of A value]

number

[0083] [Test system scheme] Figure 3 shows the principle flow sheet of the LF / LPO isolation method and the estimated mass balance of the process at the scale of one chromatographic experiment. Prior to LF / LPO isolation, 1100 L of acid whey is filtered using a ceramic TFF filter system with a pore size of less than 0.8 μm. The filtered whey (1000 L) is then pumped to an equilibrated chromatography column. The LF and LPO bound to the column are then eluted by a combination of various buffers. The eluted fractions are then concentrated and, if necessary, desalted. After drying of the concentrated protein, 60-90 g of dry LF product is obtained. The resulting slightly altered flow-through whey and whey slurry can be used separately or mixed for further downstream use or processing.

[0084] <Example 1> A monolithic column, 80 mL CIMmultus™ SO3 (BIA Separations) was equilibrated with 800 mL of buffer A (sodium phosphate or citrate buffer: 5-50 mM, pH=4.6) before loading. After equilibration, the filtered acid whey was pumped through the column until the column volume of LF and LPO was reached. Saturation of the column volume was confirmed by analyzing the flow-through sample at the outlet side of the column by the HPLC method described in the analysis section. The volume of whey pumped through the column at a flow rate of 0.24 L / min was usually 10-20 L, depending mainly on the LF / LPO concentration in the treated whey. The column was then flushed with buffer A. The separation of LF and LPO was started by flushing the column with two buffers (a mixture of sodium citrate buffer, phosphate buffer, TRIS buffer and carbonate buffer, 4-50 mM, pH=4.6 and 12.0) in a linear pH gradient mode. The pH was gradually changed linearly within the range of 4.6-12.0. The pH ranges of LPO / LF elution were 8.9-10 and 11-11.7, respectively. The result of the separation procedure was two chromatographically very well separated elution fractions of LPO and LF, which were easily further processed separately. In the subsequent steps, the fractions of isolated proteins were neutralized to pH=6 with a small amount of a suitable acidic solution, concentrated using a TFF membrane with a pore size of 1-50 kDa, and spray-dried. The final purity of LF and LPO was >98% and >70%, respectively. The C and A values ​​of LF were determined to be 71% and 3.4%, respectively.

[0085] <Example 2> A monolithic column, 80 mL CIMmultus™ SO3 (BIA Separations) was equilibrated with buffer B (sodium phosphate or citrate buffer: 5-50 mM, pH = 5.0-6.5, the same as the pH of sweet whey) before loading. Sweet whey was then run through the column until the column volume of LF and LPO was reached. Saturation of the column volume was confirmed by analyzing the flow-through sample at the outlet side of the column by the HPLC method described in the analysis section. The volume of whey pumped through the column at a flow rate of 0.24 L / min was usually 10-40 L, depending mainly on the LF / LPO concentration in the treated whey. The column was then flushed with buffer B. The separation of LF and LPO was started by flushing the column with two buffers (a mixture of sodium citrate buffer, phosphate buffer, TRIS buffer and carbonate buffer, 4-50 mM, pH=5.0 and 12.0) in a linear pH gradient mode. The pH was gradually changed linearly within the range of 5.0-12.0. The pH ranges of LPO / LF elution were 8.9-10 and 11-11.7, respectively. The result of the above operations were two chromatographically very well separated fractions of LPO and LF, which were easily further processed separately. In the subsequent steps, the fractions of isolated proteins were neutralized to pH=6 with a small amount of a suitable acidic solution, concentrated using a TFF membrane with a pore size of 1-50 kDa, and spray-dried. The final purity of LF / LPO was >98% or >70%. The C and A values ​​of LF were determined to be 70.2% and 3.9%, respectively.

[0086] <Example 3> A monolithic column, 8 L CIMmultus™ SO3-Strong CEX (BIA Separations) was equilibrated with 40-80 L of buffer C (sodium phosphate or citrate buffer with added NaCl: 5-50 mM, pH=4.6 and conductivity of 15 mS / cm) before loading. Acid whey was then loaded onto the column until the column volume of LF and LPO was reached. The column volume saturation was determined as described in the analytical section. The HPLC method was confirmed by analyzing the flow-through samples at the outlet side of the column. The volume of whey pumped into the column at a flow rate of 8 L / min was usually 1000-2000 L, depending mainly on the LF / LPO concentration in the treated whey. The column was then flushed with buffer C. Separation of LF and LPO was performed by flushing the column with two buffers (a mixture of sodium citrate buffer, phosphate buffer, TRIS buffer and carbonate buffer supplemented with NaCl, 4-50 mM, pH=4.6 and 12.0) in a linear pH gradient mode. The pH was gradually changed linearly within the range of 4.6-12.0, and the conductivity (15 mS / cm) was constant throughout the linear pH gradient. The pH ranges of LPO / LF elution were 8.2-9.3 and 10.7-11.2, respectively. The result of the above procedure was two chromatographically well separated elution fractions of LPO and LF, which were easily further processed separately. In the subsequent steps, the recovered protein fractions were first neutralized to pH=6 using a small amount of a suitable acidic solution, desalted and concentrated using a TFF membrane with a pore size of 1-50 kDa, and dried by spray drying. The final purity of LF / LPO was >98% or >75%. The C and A values ​​of LF were determined to be 74.2% and 2.5%, respectively.

[0087] <Example 4> The monolith column, 8 L CIMmultus™ SO3-Strong CEX (BIA Separations) was equilibrated with buffer C (sodium phosphate or citrate buffer: 5-50 mM, pH=5.0-6.5, the same as the pH of sweet whey) before loading. Then, acid whey was poured into the column until the column volume of LF and LPO was reached. Saturation of the column volume was confirmed by analyzing the flow-through sample at the outlet side of the column by the HPLC method described in the analysis section. The volume of whey pumped into the column at a flow rate of 8 L / min was usually 1000-2000 L, depending mainly on the LF / LPO concentration in the treated whey. Proteins with an IEP less than 7.5 were first eluted in pH step elution mode with buffer C at pH=7.5, and then separation of LF and LPO was performed by flushing the column in linear pH gradient mode using the same buffer as in Example 2. The pH was gradually changed linearly within the range of 7.5-12.0. The pH ranges of LPO / LF elution were 8.9-10 and 11-11.7, respectively. The separately collected LPO and LF elution fractions were then neutralized to pH=6 using a small amount of suitable acidic solution, concentrated using TFF membranes with pore sizes of 1-50 kDa, and dried by spray drying. The final purity of LF and LPO was >98% or >75%, respectively. The C and A values ​​of LF were determined to be 72.6% and 2.8%, respectively.

[0088] <Example 5> A monolithic column, 8 L CIMmultus™ SO3-Strong CEX (BIA Separations) was equilibrated with Buffer C (NaCl-added sodium phosphate or citrate buffer: 5-50 mM, pH=4.6 and conductivity of 15 mS / cm) before loading. Acid whey was then run through the column until the column volume of LF and LPO was reached. Saturation of the column volume was confirmed by analyzing the flow-through sample at the outlet side of the column by the HPLC method described in the analytical section. The volume of whey pumped through the column at a flow rate of 8 L / min was usually 1000-2000 L, depending mainly on the LF / LPO concentration in the treated whey. The column was then flushed with Buffer C. Proteins with an IEP less than 7.5 were first eluted in pH step elution mode with buffer C at pH=7.5, and then separation of LF and LPO was performed by flushing the column in linear pH gradient mode using the same buffer as in Example 3. The pH was gradually changed linearly in the range of 7.5-12.0, and the conductivity (15 mS / cm) was constant throughout the pH gradient. LPO / LF elution The pH ranges of were 8.2-9.3 and 10.7-11.2, respectively. The separately collected elution fractions of LPO and LF were then neutralized to pH=6 with a small amount of suitable acidic solution, concentrated using TFF membranes with pore sizes of 1-50 kDa, and dried by spray drying. The final purity of LF and LPO was >98% or >80%, respectively. The C and A values ​​of LF were determined to be 71.6% and 3.2%, respectively.

[0089] <Example 6> The monolith column, 8 L CIMmultus™ SO3-Strong CEX (BIA Separations), was equilibrated with Buffer C (sodium phosphate or citrate buffer: 5-50 mM, pH=4.6) before loading. Acid whey was then run through the column until the column volume of LF and LPO was reached. Saturation of the column volume was confirmed by analyzing the flow-through sample at the outlet side of the column by the HPLC method described in the analysis section. The volume of whey pumped through the column at a flow rate of 8 L / min was usually 1000-2000 L, depending mainly on the LF / LPO concentration in the treated whey. The column was then flushed with Buffer C. Proteins with IEP less than 7.5 were first eluted by pH step elution mode with buffer C at pH=7.5, then separation of LF and LPO was performed by flushing the column with two buffers (a mixture of sodium citrate buffer, phosphate buffer, TRIS buffer and carbonate buffer, 4-50 mM, pH=4.6 and 12.0, with NaCl added to obtain suitable conductivity). The pH was gradually changed in the range of 7.0-12.0, while the conductivity gradient was increased from 4 mS / cm to 55 mS / cm. The pH ranges of LPO / LF elution were 6.6-7.5 and 9.6-10.7, respectively. The eluted fractions of LPO and LF, which were collected separately, were then neutralized to pH=6 with a small amount of suitable acidic solution, desalted and concentrated using TFF membranes with pore sizes of 1-50 kDa, and dried by spray drying method. The final purity of LF and LPO was >98% or >85%, respectively. The C and A values ​​of LF were determined to be 76.1% and 2.0%, respectively.

[0090] (References) [1] Susana A. Gonzalez-Chavez, Sigifredo Arevalo-Gallegos, and Quintin Rascon-Cruz. Lactoferrin: structure, function and applications. International Journal of Antimicrobial Agents, 33(4): 301.e1 - 301.e8, 2009. [2] Nicolas Urtasun, Maria Fernanda Baieli, Daniela BelenHirsch, Maria Camila Martinez-Ceron, Osvaldo Cascone, and Federico Javier Wolman. Lactoperoxidase purification from whey by using dye affinity chromatography. Food and Bioproducts Processing, 103:58 - 65, 2017. [3] Lin Chen, Chen Guo, Yueping Guan, and Huizhou Liu. Isolation of lactoferrin from acid whey by magnetic affinity separation. Separation and Purification Technology, 56(2):168 - 174, 2007. [4] Rhee-M.S. Imm J.Y. Noh, K.H. Separation of lactoferrin from model whey protein mixture by reverse micelles formed by cationic surfactant. Food Sci. Biotechnol., 14:131-136., 2005. [5] Shalan Alwan Al-Mashikhi, Eunice Li-Chan, and ShuryoNakai. Separation of immunoglobulins and lactoferrin from cheese whey by chelating chromatography. Journal of Dairy Science, 71(7):1747 - 1755, 1988. [6] S. Yoshida, Z. Wei, Y. Shinmura, and N. Fukunaga. Separation of lactoferrin-a and -b from bovine colostrum. Journal of Dairy Science, 83(10):2211 - 2215, 2000. [7] Jonatan Andersson and Bo Mattiasson. Simulated moving bed technology with a simplified approach for protein purification: Separation of lactoperoxidase and lactoferrin from whey protein concentrate. Journal of Chromatography A, 1107(1 ):88 - 95, 2006. [8] Rong Rong Lu, Shi Ying Xu, Zhang Wang, and Rui Jin Yang. Isolation of lactoferrin from bovine colostrum by ultrafiltration coupled with strong cation exchange chromatography on a production scale. Journal of Membrane Science, 297(1):152 - 161, 2007. [9] T. Uchida, S. Dosako, K. Sato, and H. Kawakami. Sequential separation of lactoferrin, lactoperoxidase, and secretory component by sulfate-linked ion-exchange chromatography. Milchwissenschaft, 9(58):482-486, January 2003.

[10] O. Cascone Mariano Grasselli. Separation of lactoferrin from bovine whey by dye affinity chromatography. Netherlands Milk and Dairy Journal, 4(50):551-561, January 1996.

[11] Enrique Alvarez-Guerra and Angel Irabien. Extraction of lactoferrin with hydrophobic ionic liquids. Separation and Purification Technology, 98:432 - 440, 2012.

[12] Vojtech Adam, OndrejZitka, Petr Dolezal, Ladislav Zeman, Ales Horna, Jaromir Hubalek, Jan Sileny, Sona Krizkova, Libuse Trnkova, and Rene Kizek. Lactoferrin isolation using monolithic column coupled with spectrometric or micro-amperometric detector. Sensors (Basel), 1(8):464-487, January 2008.

[13] J.H. Nuijens and H.H. Van Veen. Isolation of lactoferrin from milk, January 19 1999. U.S. Patent No. 5861491.

[14] Conan J. Fee and Amita Chand. Capture of lactoferrin and lactoperoxidase from raw whole milk by cation exchange chromatography. Separation and Purification Technology, 48(2):143 - 149, 2006. Separation and Purification in the Food Industry.

[15] Chalore Teepakorn, Koffi Fiaty, and Catherine Charcosset. Comparison of membrane chromatography and monolith chromatography for lactoferrin and bovine serum albumin separation. Processes, 4(3), 2016.

[16] P. Milavec Zmak, H. Podgornik, J. Jancar, A. Podgornik, and A. Strancar. Transfer of gradient chromatographic methods for protein separation to convective interaction media monolithic columns. Journal of Chromatography A, 1006(1):195 - 205, 2003. International Symposium on Preparative and Industrial Chromatography and Allied Techniques.

[17] Shuichi Yamamoto and Ayako Kita. Theoretical background of short chromatographic layers: Optimization of gradient elution in short columns. Journal of Chromatography A, 1065(1):45-50, 2005. 1st Monolith Summer School.

[18] Bo Wang, Yakindra Prasad Timilsena, Ewan Blanch, and Benu Adhikari. Characteristics of bovine lactoferrin powders produced through spray and freeze drying processes. International Journal of Biological Macromolecules, 95:985–994, 2017.

[19] K. Sato and SI Dousako. Process of separation, purification and recovery milk proteins capable of binding iron, March 27 1991. No. 19900117442.

[20] K. Sato, M. Shiba, A. Shigematsu, N. Teduka, and A. Tomizawa. Method for producing lactoferrin, October 13 2004. Publication Paper No. 20040008008.

[21] G. Rowe, H. Aomari, and D. Petitclerc. New purification method of lactoferrin, November 16 2006. Public Patent PCT / CA2006 / 000780.

[22] H. Kawakami, M. Tanimoto, and S. Dousako. Process for separating and purifying lactoferrin from milk using sulfate compound, September 9 1992. European Patent No. 0348508.

[23] Z. Mozaffar, SH Ahmed, V. Saxena, and QR Miranda. Sequential separation on of whey, August 1 2000. U.S. Patent No. 6,096,870.

[24] J. Souppe. Milk protein isolate and process for its preparation, December 10 2013. U.S. Patent No. 8,603,560.

[25] Kussendrager KD, Kivits MGC, and Verver AB Process for isolating lactoferrin and lactoperoxidase from milk and milk products, and products obtained by such process, June 16 1998. Canadian Patent No. 2128111.

[26] S. Okonogi, M. Tomita, T. Tomimura, Y. Tamura, and T. Mizota. A process for producing bovine lactoferrin in high purity, July 5 2006. European Patent No. 0253395.

[27] KD Kussendrager, MGC Kivits, and AB Verver. Process for isolating lactoferrin and lactoperoxidase from milk and milk products, and products obtained by such process, January 21, 1997. U.S. Patent No. 5,596,082.

[28] Jean-Paul Perraudin. Method for production of lactoferrin, August 2015. U.S. Patent No. 9,115,211.

[29] Kevin Neil Pearce Shaojiang Chen. Method of preparing low-iron lactoferrin, February 2012. European Patent Application Publication No. 2421894.

[30] Hassan Mohamed Hassan Abdalla. Method for purifying lactoferrin, December 2014. U.S. Patent No. 9,458,225.

[31] Jan H. Nuijens Veen Harry H. Van. Isolation of lactoferrin from milk, August 1995. WO 1995 / 022258.

[32] Linda Voswinkel, Thomas Vogel, and Ulrich Kulozik. Impact of the iron saturation of bovine lactoferrin on adsorption to a strong cation exchanger membrane. International Dairy Journal, 56:134 - 140, 2016.

[33] Satoshi Ito, Katsuya Ikuta, Daisuke Kato, Kotoe Shibusa, Noriyasu Niizeki, Hiroki Tanaka, Lynda Addo, Yasumichi Toki, Mayumi Hatayama, Junki Inamura, MotohiroShindo, Katsunori Sasaki, Naomi Iizuka, Mikihiro Fujiya, Yoshihiro Torimoto, and Yutaka Kohgo. Non-transferrin-bound iron assay system utilizing a conventional automated analyzer. ClinChem Acta, 437:129-135, 2014.

[34] Robert J. Hilton, Matthew C. Seare, N. David Andros, Zachary Kenealey, Catherine Matthias Orozco, Michael Webb, and Richard K. Watt. Phosphate inhibits in vitro Fe3+ loading into transferrin by forming a soluble Fe(iii) phosphate complex: A potential non-transferrin bound iron species. Journal of Inorganic Biochemistry, 110:1–7, 2012.

Claims

1. A method for producing a fraction containing lactoferrin protein and / or lactoperoxidase protein from a raw material containing at least one of these proteins, comprising: The raw material is selected from the group consisting of milk, colostrum, acid or sweet whey; A chromatographic separation process using a monolithic column with strong cation exchange properties is used, The method, wherein the separation process utilizes a pH gradient or a combination of pH and salt gradient elution after introduction of the raw material into the column.

2. 2. The method of claim 1, wherein the pH gradient begins within a pH range of about 4.0 to less than about 8.

0.

3. 3. The method of claim 1 or 2, wherein the pH gradient terminates within a pH range of about 8 to less than 13.

4. The method of any one of claims 1 to 3, wherein the feed is filtered prior to introduction of the feed into the column.

5. 5. The method according to any one of claims 1 to 4, wherein fraction A is collected which elutes in the pH range of about 8 to less than about 11, in particular in the pH range of about 8.9 to about 10, or in the pH range of about 6.6 to about 7.5 at a higher conductivity in the range of about 5 to 55 mS / cm.

6. 6. The method according to any one of claims 1 to 5, wherein fraction B is collected which elutes in the pH range of greater than about 10.4 to about 12, in particular in the pH range of greater than about 11 to about 11.7, or in the pH range of about 9.6 to about 10.7 at a higher conductivity in the range of about 5 to 55 mS / cm.

7. The chromatographic separation process comprises: (i) adjusting the pH of the feedstock to a value below pH 7, in particular below pH 6.5; (ii) contacting the feed of step (i) with a monolith column having strong cation exchange properties; and then (iii) passing a pH gradient buffer through the column, thereby increasing the pH value; and (iv) recovering fraction A which elutes in the pH range of about 8 to less than about 11, in particular in the pH range of about 8.0 to about 10, preferably in the pH range of about 8.2 to about 10, more preferably in the pH range of about 8.9 to about 10, or in the pH range of about 6.6 to about 7.5 at a higher conductivity in the range of about 5 to 55 mS / cm, and which typically contains lactoperoxidase; and / or (v) recovering fraction B which elutes in the pH range of about >10 to about 12.0, preferably about >10.4 to about 12, more preferably about >11.0 to 12.0, especially about >11 to about 11.7, or about 9.6 to about 10.7 at a higher conductivity of about 5-55 mS / cm, and which typically contains lactoferrin; (vi) optionally further processing said fraction A and / or said fraction B, in particular by treatments such as neutralization, concentration and storage; The method according to any one of claims 1 to 6, comprising:

8. 8. The method of claim 7, wherein the feedstock is filtered prior to step (ii) or the monolith column is equilibrated prior to step (ii) with an equilibration buffer having a pH value of less than about 7, in particular less than about 6.

5.

9. The monolith column having strong cation exchange properties is -SO 3 H-modified monolith column, -COOH-modified monolith column, -OSO 3 H-modified monolith column or -OPO 3 The method according to any one of claims 1 to 8, wherein the column is selected from the group consisting of H-modified monolith columns.

10. 10. The method according to any one of claims 1 to 9, wherein the salt gradient is effected by a salt concentration, in particular the salt gradient corresponds to a conductivity in the range of about 5 mS / cm to about 55 mS / cm.

11. The method according to any one of claims 1 to 10, wherein prior to step (iii) or step (iv), the column is flushed with the equilibration buffer according to claim 8.

12. The method according to any one of claims 1 to 11, wherein the lactoferrin and lactoperoxidase containing fraction is dried, in particular by spray drying.

13. 13. The method according to any one of claims 1 to 12, wherein the lactoferrin has a purity of more than 90% and the lactoperoxidase has a purity of more than 50%, in particular the C value of the lactoferrin is more than 50% and the A value of the lactoferrin is more than 1%.

14. 14. The method of any one of claims 1 to 13, wherein after step (iv) or step (v), the column is washed by flushing the column with a buffer having a pH above about 12.

15. A composition comprising lactoferrin having a C value of greater than 60% and an A value of greater than 1%.

16. 16. The composition of claim 15, wherein the C value is 70% or more and the A value is 2% or more.

17. A composition comprising lactoferrin or lactoperoxidase, obtainable by the method according to any one of claims 1 to 14.